A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATPbinding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.
Multi-drug resistance (MDR) occurs when cancer cells acquire simultaneous resistance to a diverse class of chemotherapeutic agents which have no structural or functional similarities. One mechanism by which tumor cells achieve MDR is via the active efflux of chemotherapies through membrane drug transport proteins. ATP-binding cassette (ABC) proteins act as ATPdependent drug efflux pumps, which actively extrude certain classes of chemotherapeutic agents and toxins from cells, causing a decrease in intracellular drug accumulation and rendering the agents ineffective. To date, 48 members of the ABC transporter family have been identified in humans (Szakacs et al., 2006) . These genes are classified into seven structural subfamilies (ABCA through ABCG) which have a broad range of expression in normal and malignant tissues. Although ABC transporters are highly expressed in stem cells and during tissue regeneration, their regulation in the context of cancer is poorly understood (Szakacs et al., 2006) .
The hedgehog (Hh) signaling pathway is critical for growth and differentiation during embryonic development and is required for maintenance of somatic stem cells (Ingham and McMahon, 2001) . Hh ligands (Sonic, Desert and Indian) bind to and antagonize the cell surface receptor patched (PTCH), relieving the PTCHmediated suppression of the transmembrane protein smoothened (SMO). SMO then initiates an intracellular signaling cascade that leads to the activation and nuclear translocation of the Gli family of transcription factors (Gli-1, 2 and 3). Gli family members mediate transcription of genes controlling proliferation, differentiation and survival (Ingham and McMahon, 2001; Ruel et al., 2003) . Aberrations in hedgehog signaling have been found in cancers from a wide range of tissues (Kubo and Corley, 2004) , resulting from mutations in Hh pathway signaling components (Reifenberger et al., 2005; Lindstrom et al., 2006) and an increase in endogenous Hh ligands (Berman et al., 2003; SimsMourtada et al., 2006) .
We have shown previously that Hh pathway activation is associated with therapeutic resistance in esophageal adenocarcinomas (Sims-Mourtada et al., 2006) . A significant upregulation of Shh and Gli-1 expression was observed in the majority of residual tumors after chemoradiotherapy (CRT), suggesting that Hh signaling may contribute to cancer resistance. Moreover, a significant increase in Hh signaling was observed during tumor repopulation after CRT in an esophageal tumor model that resembles tumor regrowth after an ineffective treatment. The activation of the Hh signaling pathway observed in both CRT-resistant residual esophageal carcinoma specimens and animal tumor xenografts suggests that Hh signaling may promote survival of tumor clonogens after CRT.
To further determine the role of Hh signaling in chemoresistance, we examined the effect of Hh signaling inhibition on the responses of cell lines of different tumor types with varying levels of Shh and Gli-1 expression (Figure 1a) , to structurally unrelated chemotherapy agents. We treated SEG-1 esophageal adenocarcinoma, LnCaP androgen-receptor-positive prostate carcinoma, PC3 androgen-receptor-negative prostate carcinoma and DM14 metastatic squamous cell carcinoma with two different concentrations (2 mM and 5 mM) of the steroidal alkyloid cyclopamine, which have been shown to inhibit Gli-1 nuclear translocation by interfering with the activation of SMO. (Chen et al., 2002; Sims-Mourtada et al., 2006) . Cells were cultured for 24 h and then treated with low doses of docetaxel (DOC), methotrexate (MTX) or etoposide (VP-16). Treatment with 2 mM cyclopamine had almost no effect on cell survival. Cells treated with 5 mM cyclopamine showed a slight decrease in survival and this decrease correlated with Gli-1 expression (Figure 1b-d) . Lowdose chemotherapy alone had little effect on cell survival 48 h after treatment (Figure 1b-d) . However, the combination of low-dose chemotherapy and cyclopamine resulted in enhanced cell killing. This phenomenon occurred independently of the cytotoxic mechanisms of the chemotherapeutic agents, indicating that the increase in cell killing may have resulted from a common pathway. Of note is that cyclopamine had little effect on drug-induced death of LnCaP cells, which have little endogenous activation of Hh signaling in their early passages, indicating that the effect of cyclopamine is specific to the Hh pathway.
In addition, to determine whether Hh signaling can promote resistance to chemotherapy, we tested whether exogenous Sonic Hh (Shh) ligand is capable of protecting against death induced by DOC, MTX or VP-16. LnCaP and Seg-1 cells, which have the lowest background expression of Hh signaling of the four lines tested were chosen for studies using exogenous Shh ligand. Cells were pretreated with 200 ng/ml Shh ligand 24 h before treatment with DOC, MTX or VP-16 and survival was determined by clonogenic assay. We observed a significant increase in clonogenic survival after chemotherapy in cells stimulated with Shh ligand, as compared with those treated with chemotherapeutic agents alone (Figure 2a) .
These results led us to suspect that the resistance to these structurally unrelated drugs might be a result of active drug efflux from tumor cells. Therefore, we sought to determine whether Hh signaling affects intracellular drug accumulation. Treatment of SEG-1 and PC3 cells with cyclopamine resulted in an increase in intracellular 3 H-labeled drug (Taxol, MTX or VP-16) accumulation . However, no effect on drug uptake was observed in LnCaP cells treated with cyclopamine, which is consistent with the level of endogenous Hh pathway activity. On the other hand, treatment with Shh ligand resulted in a significant decrease in drug uptake. Simultaneous treatment of Shh (Figure 3a) . Owing to the high background expression of Shh ligand, PC3 and DM14 cell lines were not included in these studies. We further explored the ability of Hh signaling to regulate expression of ABC transporter proteins by blockade of Hh signaling by treatment of SEG-1, PC3 and DM14 cells with Gli-1-specific small interfering RNA (siRNA) or treatment with low-or high-dose cyclopamine (Figure 3b ). Blockade of Hh signaling resulted in a decrease in Gli-1 expression, which corresponded to a decrease in expression of MDR1 and BCRP. LnCaP cells were excluded from these studies because they do not exhibit detectable levels of Hh signaling.
To determine whether expression of MDR1 and BCRP is required for Hh-induced drug efflux, we performed uptake studies in combination with targeted knockdown of MDR1 and BCRP by siRNA. Knockdown of MDR1 and BCRP protein expression after siRNA transfection was confirmed by Western analysis (data not shown). Inhibition of transporter expression decreased the effect of Shh stimulation on drug efflux in SEG-1 cells for 3 H-labeled Taxol, MTX and VP-16 (Figure 4a-c) . Although we observed an effect on Shh-induced drug transport with individual siRNAs, the most significant effect was seen with the combination of MDR1 and BCRP inhibition, indicating simultaneous regulation of different ABC transporters by the Hh pathway. To determine whether inhibition of transporter expression affects Shh-induced chemoresistance, we performed survival assays of cells in which expression of MDR1, BCRP, or both was inhibited. Consistent with the drug uptake studies, inhibition of transporter expression significantly decreased the effect Figure 4 Effect of Shh on drug efflux and chemoresistance is dependent on expression of MDR1 and BCRP. A decrease in Shhmediated drug efflux is observed in cells transfected with MDR1 siRNA, BCRP siRNA, or a combination of both as compared with untreated cells. SEG-1 cells were transfected with 100 nM control siRNA, MDR1 siRNA, BCRP siRNA, or a combination of MDR1 and BCRP siRNA (Silencer siRNA, Ambion, Austin, TX, USA). Cells were allowed to grow for 12 h after transfection. Then, the media was replaced with media containing at 200 ng/ml SHH ligand and cells were cultured for 24 h. Cells were then treated with (a) 3 H-labeled Taxol, (b) MTX or (c) VP-16, cultured for an additional 16 h and radioactivity of cell lysates was determined as described above. Data are shown as the percentages of unstimulated cell uptake. of Shh on the survival of cells treated with DOC when compared with controls, with the greatest effect observed in cells in which expression of both MDR1 and BCRP was inhibited. We observed a similar effect of treatment with MTX and VP-16 ( Supplementary  Figure 1a and b) . While inhibition of ABC transporter expression significantly reduced the effect of Hh activation on chemoresistance, cells treated with exogenous Shh ligand still had a survival advantage over control cells, even in the presence of MDR1 and BCRP siRNA. Regulation of drug efflux is an important mechanism by which the Hh pathway promotes chemoresistance, but it is not the sole causal factor. Previous studies by our lab and others (Berman et al., 2003; Bigelow et al., 2004; Sims-Mourtada et al., 2006) have shown that the Hh pathway regulates cell cycle progression and apoptotic resistance; this likely contributes to Hh-induced chemoresistance.
Recent studies have suggested that pretreatment expression of ABC transporters predicts poor clinical response to chemotherapy in a number of tumors (Doyle and Ross, 2003; Chintamani et al., 2005; Takara et al., 2006) . However, due to overlapping roles of ABC transporters in normal physiology and detoxification, tactics aimed at suppressing their function to enhance the effect of chemotherapy have not been fruitful (PerezTomas, 2006; Takara et al., 2006) . Understanding the regulation of ABC transporters in tumor cells may lead to new therapeutic strategies. Our results indicate that expression of multiple ABC transporters can be regulated by Hh signaling. However, whether this phenomenon occurs through direct transcriptional regulation of transporter genes by Gli-1 remains to be determined. While potential Gli-1 binding sites are found in promoters of multiple ABC transporters from different subfamilies (unpublished observation), Hh signaling is known to influence the differentiation state of normal and malignant tissues (Okano-Uchida et al., 2004) , and Shh-induced changes in differentiation status could also indirectly influence the simultaneous expression of multiple members of the ABC transporter family, which are known to be expressed in undifferentiated cells during development (Bunting et al., 2000; Zhou et al., 2001) .
In conclusion, we show that Hh signaling increases resistance to multiple structurally unrelated chemotherapeutic agents in part through promotion of drug efflux by the regulating of MDR1 and BCRP expression. Our discovery that Hh signaling regulates ABC transporter expression in tumors could provide potentially a novel therapeutic strategy because inhibiting Hh signaling may not only affect tumor proliferation as we have shown previously, but may also increase chemotherapeutic effect, and result in improved treatment responses.
